Abbott is revolutionizing personal health monitoring with its biowearables, advanced sensors designed to provide real-time glucose data directly to a user’s smartphone. Building on its medical success with FreeStyle Libre, used by approximately six million people worldwide, the company has now introduced Lingo and Libre Rio biowearables. Lingo is tailored for general consumers aiming to enhance overall wellness, while Libre Rio targets individuals with Type 2 diabetes who do not use insulin, supporting lifestyle-based diabetes management. Both devices offer over-the-counter accessibility and feature biosensors that use a minimally invasive filament to measure interstitial fluid for continuous glucose tracking. These devices support users to make proactive health decisions, improving energy, weight management, and overall well-being.
Abbott's biowearables portfolio represents a significant leap forward, broadening access to advanced health technology beyond traditional medical applications. The FreeStyle Libre system remains a cornerstone for individuals managing diabetes, and studies have demonstrated consistent positive health outcomes. Abbott's vision for biowearables extends beyond glucose monitoring, with plans to explore biomarkers like ketones and lactate, potentially addressing broader aspects of health and wellness. With devices like Lingo and Libre Rio, Abbott aims to shape a future where personalized health insights are available to diverse populations, from athletes to those managing chronic conditions.
